Kamil Ali-Jackson bought stock once, on Jun 15, 2021

Kamil Ali-Jackson is an experienced biopharmaceutical executive and attorney who serves as a director of Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), having joined the company’s board in December 2021.( She brings nearly four decades of life sciences industry experience, with particular expertise in licensing, joint ventures, mergers and acquisitions, and strategic transactions that support corporate growth.( At Rigel, she contributes board-level oversight informed by her extensive background in legal, compliance, and corporate governance roles across public and venture-backed companies.(

Prior to joining Rigel’s board, Ali-Jackson was the chief legal officer, chief compliance officer, and corporate secretary of Aclaris Therapeutics, Inc., a publicly traded, clinical-stage biopharmaceutical company she co‑founded in 2012 and helped take public in 2015, retiring from those roles in January 2022.( She has co‑founded and successfully transitioned multiple specialty and biopharmaceutical companies through multimillion‑dollar acquisitions by global life sciences firms, raising more than $1 billion in private and public equity and debt financings and helping create over 300 jobs.( A graduate of Princeton University (Class of 1981), she is also a board member of PDS Biotechnology and Moda Operandi, and an advisor to several other life science companies, reflecting her broader influence across both the biotechnology and consumer sectors.(

Written by Perplexity from public sources.